Editorial review pending — noindex
This page remains under independent editorial review (reviewPending). Visible but noindexed.
Assay warning — GDF-8 (myostatin) cross-reactivity
Early circulating GDF-11 decline measurements used SOMAmer and antibody reagents that also bind myostatin (GDF-8). Treat 2013–2014 “GDF-11-specific” blood-level claims as assay-contaminated unless confirmed with methods that discriminate the two homologs (~90% identity in the mature domain).
Section 1 of 6Overview
Overview
GDF-11 (growth/differentiation factor 11; also BMP-11) is an endogenous TGF-β/BMP-family protein encoded by human gene GDF11 (Gene ID 10220; UniProt O95390, precursor 407 aa). It is closely related to myostatin (GDF-8) — the similarity drives the assay problem that sits at the centre of the longevity debate.
This is not a short “research peptide” in the Semax/CJC catalog sense. Recombinant laboratory protein and any grey-market “GDF-11 vials” must be kept separate from a nonexistent approved medicine.
Section 2 of 6Identity
Identity
| Property | Value |
|---|---|
| Preferred name | Growth/differentiation factor 11 |
| Alias | Bone morphogenetic protein 11 (BMP-11) |
| Gene | GDF11 (10220) |
| UniProt | O95390 |
| Class | TGF-β superfamily; myostatin-near |
| Small-molecule PubChem CID | None (protein, not a small RC peptide) |
Section 3 of 6Landmark studies (contested arc)
Landmark studies (contested arc)
Loffredo et al., Cell 2013 (PMID 23663781)
Heterochronic parabiosis nominated GDF-11; reported age-related decline and reversal of age-related cardiac hypertrophy in mice. Mouse morphology endpoints — not a human clinical rejuvenation trial.
Sinha et al., Science 2014 (PMID 24797481)
Reported restoring systemic GDF-11 improved skeletal muscle / stem-cell function in aged mice — same assay lineage later criticised for GDF-8 cross-reactivity.
Egerman et al., Cell Metabolism 2015 (PMID 26001423)
Showed SOMAmer and Abcam antibody bind both GDF-11 and myostatin; reported GDF-11 increases with age in their western interpretation and inhibits skeletal muscle regeneration — opposite direction from Sinha 2014 for muscle.
Poggioli et al., Circ Res 2016 (PMID 26489925)
Argued Egerman’s ~25 kDa band partly reflected Ig light-chain cross-reactivity; reported decline of circulating GDF11/8 with age; rGDF-11 activated SMAD2/3 and reduced cardiac mass in short mouse treatments.
Smith et al., Circ Res 2015 (PMID 26383970 (opens in a new tab))
Independent replication attempt (Temple University with Boehringer Ingelheim): recombinant GDF-11 for 28 days in 24-month-old mice raised GDF-11 levels but did not change heart weight, cardiac function or myocyte size. The authors also found no age-related pathological hypertrophy to reverse in their old mice.
Schafer et al., Cell Metab 2016 (PMID 27304512 (opens in a new tab))
Human study with a GDF-11-specific LC-MS/MS assay: myostatin, not GDF-11, declined with age in healthy men, and neither changed with age in women. In older adults with severe aortic stenosis, higher GDF-11 was associated with frailty, diabetes and more adverse events after valve surgery. This is the opposite of the "GDF-11 falls with age and should be replaced" framing.
Harper et al., Circ Res 2018 (PMID 30571461 (opens in a new tab))
In a mouse pressure-overload model, GDF-11 reduced pathological hypertrophy, but the highest dose tested caused severe cachexia (muscle and organ wasting) and death. The authors warned that GDF-11 therapy "could have potentially devastating actions on the heart and other tissues".
Ben Driss et al., 2023 (PMID 38235060)
Review by the originating groups (Wagers, Lee, Rubin; Walker is a co-author): states that their initial suggestion that systemic GDF-11 declines with age was incorrect (the signal was dominated by GDF-8), and that "the simple concept that GDF11 levels decline with aging and can be replaced" is incorrect. MS does not clearly support a circulating increase; subtypes remain under study. Conflict of interest: per the paper, Lee, Rubin and Wagers are co-founders of and hold equity in Elevian, Inc., which also funded research in their labs, and several authors hold GDF-11/GDF-8 patents. Its remaining positive framing of GDF-11 therapy should be read with that in mind.
Section 4 of 6Claims vs evidence
Claims vs evidence
| Claim | Assessment |
|---|---|
| Circulating GDF-11 falls with age (2013–14 framing) | Contested / originally not GDF-11-specific |
| Rejuvenates aged heart (mice) | Model-limited; disputed — not replicated by Smith 2015 |
| Rejuvenates skeletal muscle | Contradicted by Egerman 2015 in their models |
| Circulating GDF-11 falls with age in humans | Not supported — specific assay found no decline; higher levels linked to frailty (Schafer 2016) |
| Safe to supplement | Not shown — high doses caused cachexia and death in mice (Harper 2018) |
| Proven clinical rejuvenation factor | False — no approved product; no identified human RCT |
| GDF-11 = myostatin | False — homologs; assay confusion |
| Human anti-aging dose | Reject |
Section 5 of 6Human / regulatory status
Human / regulatory status
No approved “GDF-11” medicine. No identified controlled human rejuvenation RCT with recombinant GDF-11. CT.gov name hits in the dossier pass were largely aging/biomarker noise, not clear GDF-11 drug trials. Pathway drugs such as ligand traps (e.g. luspatercept class) are not GDF-11 replacement therapy.
Section 6 of 6What this page intentionally omits
What this page intentionally omits
- Any rejuvenation / anti-aging dose
- Equating vendor vials with UniProt biology
- Presenting 2013–14 media claims as settled science